Abstract
Objective
Cisplatin (CDDP)-based chemotherapy is a first-line, drug regimen for muscle-invasive bladder cancer (BC) and metastatic bladder cancer. Clinically, resistance to CDDP restricts the clinical benefit of some bladder cancer patients. AT-rich interaction domain 1A (ARID1A) gene mutation occurs frequently in bladder cancer; however, the role of CDDP sensitivity in BC has not been studied.
Methods
We established ARID1A knockout BC cell lines using CRISPR/Cas9 technology. IC50 determination, flow cytometry analysis of apoptosis, and tumor xenograft assays were performed to verify changes in the CDDP sensitivity of BC cells losing ARID1A. qRT-PCR, Western blotting, RNA interference, bioinformatic analysis, and ChIP-qPCR analysis were performed to further explore the potential mechanism of ARID1A inactivation in CDDP sensitivity in BC.
Results
It was found that ARID1A inactivation was associated with CDDP resistance in BC cells. Mechanically, loss of ARID1A promoted the expression of eukaryotic translation initiation factor 4A3 (EIF4A3) through epigenetic regulation. Increased expression of EIF4A3 promoted the expression of hsa_circ_0008399 (circ0008399), a novel circular RNA (circRNA) identified in our previous study, which, to some extent, showed that ARID1A deletion caused CDDP resistance through the inhibitory effect of circ0008399 on the apoptosis of BC cells. Importantly, EIF4A3-IN-2 specifically inhibited the activity of EIF4A3 to reduce circ0008399 production and restored the sensitivity of ARID1A inactivated BC cells to CDDP.
Conclusion
Our research deepens the understanding of the mechanisms of CDDP resistance in BC and elucidates a potential strategy to improve the efficacy of CDDP in BC patients with ARID1A deletion through combination therapy targeting EIF4A3.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Change history
13 December 2023
An Erratum to this paper has been published: https://doi.org/10.1007/s11596-023-2819-1
04 December 2023
An Erratum to this paper has been published: https://doi.org/10.1007/s11596-023-2819-1
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021,71(3):209–249
Tavora F, Epstein JI. Bladder cancer, pathological classification and staging. BJU Int, 2008,102(9 Pt B):1216–1220
Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol, 2000,163(1):73–78
Kamoun A, de Reynies A, Allory Y, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol, 2020,77(4):420–433
Kamat AM, Hegarty PK, Gee JR, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol, 2013,63(1):4–15
Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol, 2021,79(1):82–104
Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene, 2012, 31(15):1869–83
Valle JW, Lamarca A, Goyal L, et al. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov, 2017,7(9):943–962
Lu C, Allis CD. SWI/SNF complex in cancer. Nat Genet, 2017,49(2):178–179
Wu JN, Roberts CW. ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov, 2013,3(1):35–43
Mathur R, Alver BH, San Roman AK, et al. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. Nat Genet, 2017,49(2):296–302
Wu RC, Wang TL, Shih Ie M. The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther, 2014,15(6):655–664
Megino-Luque C, Siso P, Mota-Martorell N, et al. ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma. Mol Oncol, 2022,16(11):2235–2259
Elkhadragy L, Dasteh Goli K, Totura WM, et al. Effect of CRISPR Knockout of AXIN1 or ARID1A on Proliferation and Migration of Porcine Hepatocellular Carcinoma. Front Oncol, 2022,12:904031
Shang XY, Shi Y, He DD, et al. ARID1A deficiency weakens BRG1-RAD21 interaction that jeopardizes chromatin compactness and drives liver cancer cell metastasis. Cell Death Dis, 2021,12(11):990
Liu X, Dai SK, Liu PP, et al. Arid1a regulates neural stem/progenitor cell proliferation and differentiation during cortical development. Cell Prolif, 2021,54(11):e13124
Zhang FK, Ni QZ, Wang K, et al. Targeting USP9X-AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol, 2022,14(1):101–127
Lyu C, Zhang Y, Zhou X, et al. ARID1A gene silencing reduces the sensitivity of ovarian clear cell carcinoma to cisplatin. Exp Ther Med, 2016,12(6):4067–4071
Nigro JM, Cho KR, Fearon ER, et al. Scrambled exons. Cell, 1991,64(3):607–613
Goodall GJ, Wickramasinghe VO. RNA in cancer. Nat Rev Cancer, 2021,21(1):22–36
Li Y, Zheng F, Xiao X, et al. CircHIPK3 sponges miR-558 to suppress heparanase expression in bladder cancer cells. EMBO Rep, 2017,18(9):1646–1659
Xie F, Li Y, Wang M, et al. Circular RNA BCRC-3 suppresses bladder cancer proliferation through miR-182-5p/p27 axis. Mol Cancer, 2018,17(1):144
Xie F, Xiao X, Tao D, et al. circNR3C1 Suppresses Bladder Cancer Progression through Acting as an Endogenous Blocker of BRD4/C-myc Complex. Mol Ther Nucleic Acids, 2020,22:510–519
Liu F, Zhang H, Xie F, et al. Correction: Hsa_circ_0001361 promotes bladder cancer invasion and metastasis through miR-491-5p/MMP9 axis. Oncogene, 2022,41(35):4183
Zhang H, Xiao X, Wei W, et al. CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutSalpha/ATM-p73 axis in bladder cancer. Mol Cancer, 2021,20(1):70
Wei W, Sun J, Zhang H, et al. Circ0008399 Interaction with WTAP Promotes Assembly and Activity of the m(6)A Methyltransferase Complex and Promotes Cisplatin Resistance in Bladder Cancer. Cancer Res, 2021,81(24):6142–6156
Iwatani-Yoshihara M, Ito M, Ishibashi Y, et al. Discovery and Characterization of a Eukaryotic Initiation Factor 4A-3-Selective Inhibitor That Suppresses Nonsense-Mediated mRNA Decay. ACS Chem Biol, 2017,12(7):1760–1768
Xu Y, Zhang S, Liao X, et al. Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-kappaB/bone remodeling factors signaling. Mol Cancer, 2021,20(1):98
Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature, 2010, 468 (7327):1067–1073
Tao J, Lu Q, Wu D, et al. microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncol Rep, 2011,25(6):1721–1729
Nagarajan S, Rao SV, Sutton J, et al. ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response. Nat Genet, 2020,52(2):187–197
Liu X, Li Z, Wang Z, et al. Chromatin Remodeling Induced by ARID1A Loss in Lung Cancer Promotes Glycolysis and Confers JQ1 Vulnerability. Cancer Res, 2022,82(5):791–804
Mei S, Qin Q, Wu Q, et al. Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse. Nucleic Acids Res, 2017,45(D1):D658–D662
Iyer G, Rosenberg JE. Novel therapies in urothelial carcinoma: a biomarker-driven approach. Ann Oncol, 2018,29(12):2302–2312
von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol, 2000,18(17):3068–3077
Katagiri A, Nakayama K, Rahman MT, et al. Loss of ARID1A expression is related to shorter progressionfree survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol, 2012,25(2):282–288
Shi H, Tao T, Abraham BJ, et al. ARID1A loss in neuroblastoma promotes the adrenergic-to-mesenchymal transition by regulating enhancer-mediated gene expression. Sci Adv, 2020,6(29):eaaz3440
Wang X, Sansam CG, Thom CS, et al. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. Cancer Res, 2009,69(20):8094–8101
Garczyk S, Schneider U, Lurje I, et al. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response? PLoS One, 2018,13(8):e0202965
Li J, Lu S, Lombardo K, et al. ARID1A alteration in aggressive urothelial carcinoma and variants of urothelial carcinoma. Hum Pathol, 2016,55:17–23
Wang F, Dong X, Yang F, et al. Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing. Front Genet, 2022,13:831146
Conde M, Frew IJ. Therapeutic significance of ARID1A mutation in bladder cancer. Neoplasia (New York, NY), 2022,31:100814
Xu G, Chhangawala S, Cocco E, et al. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nat Genet, 2020,52(2):198–207
Yu C, Lei X, Chen F, et al. ARID1A loss derepresses a group of human endogenous retrovirus-H loci to modulate BRD4-dependent transcription. Nat Commun, 2022,13(1):3501
Conn SJ, Pillman KA, Toubia J, et al. The RNA binding protein quaking regulates formation of circRNAs. Cell, 2015,160(6):1125–34
Chan CC, Dostie J, Diem MD, et al. eIF4A3 is a novel component of the exon junction complex. RNA, 2004,10(2):200–209
Chen D, Wang Y, Yang F, et al. The circRAB3IPMediated by eIF4A3 and LEF1 Contributes to Enzalutamide Resistance in Prostate Cancer by Targeting miR-133a-3p/miR-133b/SGK1 Pathway. Front Oncol, 2021,11:752573
Wei Y, Lu C, Zhou P, et al. EIF4A3-induced circular RNAASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1-2 signaling. Neuro Oncol, 2021,23(4):611–624
Feng ZH, Zheng L, Yao T, et al. EIF4A3-induced circular RNA PRKAR1B promotes osteosarcoma progression by miR-361-3p-mediated induction of FZD4 expression. Cell Death Dis, 2021,12(11):1025
Author information
Authors and Affiliations
Corresponding authors
Additional information
Conflict of Interest Statement
The authors declare that they have no conflicts of interest.
This work was supported by grants from the National Natural Science Foundation of China (No. 81974396, No. 81874091, No. 82072840, and No. 82102734), the Natural Science Foundation of Hubei Province (No. 2020CFB829), and the Health Commission of Hubei Province Scientific Research Project (No. WJ2021F081).
Supplementary Data
Rights and permissions
About this article
Cite this article
Jiang, Yk., Shuai, Yj., Ding, Hm. et al. ARID1A Inactivation Increases Expression of circ0008399 and Promotes Cisplatin Resistance in Bladder Cancer. CURR MED SCI 43, 560–571 (2023). https://doi.org/10.1007/s11596-023-2731-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-023-2731-8